In keeping with the organization’s vison to act as a convener of key experts across sectors, Shatterproof has launched a national advisory committee for ATLAS® (Addiction Treatment Locator Assessment and Standards platform) and the addiction treatment field at large.
The National Addiction Treatment Quality Committee (NATQC) is a diverse group of industry experts convened by Shatterproof, representing federal and state agencies, addiction treatment providers, health systems, consumer advocacy groups, academic institutions, and healthcare payers and purchasers. Members lend their expertise to help Shatterproof develop and evolve ATLAS as it expands to become a key national resource for identifying quality addiction treatment.
NATQC builds on the existing efforts of state-based ATLAS advisory committees and the Shatterproof Substance Use Disorder Treatment Task Force. Committee members meet at least three times per year to provide input in key areas based on subject matter expertise.
Provides feedback and recommendations related to including health plan claims-based measures as a key data source. Participants share information related to the impact/potential impact of the measures on providers, such as how best to ensure “apples-to-apples” comparison and where risk adjustment may be necessary.
Provides feedback on the provider reporting process, professional portals and alignment with existing quality measurement and reporting efforts.
Examines how well existing quality measures are structured to align with what is currently happening in the telemedicine space, how telemedicine can help address access issues within the treatment system, and how to add telehealth providers to ATLAS in an equitable way.
Provides feedback on the patient journey through ATLAS, offers suggestions on how to streamline, additional functionality to build into the search and facility profiles, and suggestions related to the patient experience feedback section of ATLAS.
Owner, Park Consulting and Staffing Services
Assistant Professor, Department of Psychiatry, University of Nebraska Medical Center (UNMC)
Chief Quality and Science Officer, American Society of Addiction Medicine (ASAM)
Vice President of Clinical Services, U.S.VETS
Vice President of Health Care Ratings, The Leapfrog Group
Director for Substance Use Disorders and Justice-Involved Populations, Community Catalyst
Medical Director, American Academy of Addiction Psychiatry (AAAP)
Managing Director of Advocacy and Organizing, PrEP4All
Esther Ting Memorial Professor, Department of Psychiatry and Behavioral Sciences, Stanford University
President and CEO, National Council for Mental Wellbeing
Elizabeth R. Spallin Professor of Psychiatry in Addiction Medicine, Harvard Medical School
Medical Director, Pivot Onsite-Innovations
Associate Commissioner, NYS Office of Alcoholism and Substance Abuse Services
Director, Duke-Margolis Center for Health Policy, Duke University
Senior Consultant, Technical Assistance Collaborative
Executive Director, Clinical Performance and Transformation, AHIP
Assistant Director, Federal Advocacy Group, American Medical Association’s (AMA)
Chief Operating Officer, Faces & Voices of Recovery
Director, Center for Clinical Trials Network, NIDA/NIH
Senior Vice President, Northeast Business Group on Health (NEBGH)
Vice President, Research and Analysis, National Committee for Quality Assurance